PROM1 and liver cancer: To ensure the conjugation of DOX molecules does not compromise the binding capacity of the original aptamer sequence, it is critical to evaluate if CD133 aptamer-DOX conjugates can successfully deliver DOX into the CD133-expressing liver cancer cells.